- Home
- H vs NBIX Comparison
H vs NBIX Comparison
Compare H & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- H
- NBIX
- Stock Information
- Founded
- H 1957
- NBIX 1992
- Country
- H United States
- NBIX United States
- Employees
- H N/A
- NBIX N/A
- Industry
- H Hotels/Resorts
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- H Consumer Discretionary
- NBIX Health Care
- Exchange
- H Nasdaq
- NBIX Nasdaq
- Market Cap
- H 15.5B
- NBIX 13.7B
- IPO Year
- H 2009
- NBIX 1996
- Fundamental
- Price
- H $161.04
- NBIX $135.42
- Analyst Decision
- H Buy
- NBIX Buy
- Analyst Count
- H 19
- NBIX 22
- Target Price
- H $152.39
- NBIX $166.00
- AVG Volume (30 Days)
- H 631.6K
- NBIX 997.6K
- Earning Date
- H 02-13-2025
- NBIX 02-05-2025
- Dividend Yield
- H 0.38%
- NBIX N/A
- EPS Growth
- H 192.44
- NBIX 97.40
- EPS
- H 13.18
- NBIX 3.73
- Revenue
- H $6,462,000,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- H $2.40
- NBIX $27.07
- Revenue Next Year
- H $3.57
- NBIX $16.60
- P/E Ratio
- H $12.13
- NBIX $36.33
- Revenue Growth
- H 4.01
- NBIX 25.72
- 52 Week Low
- H $124.40
- NBIX $110.95
- 52 Week High
- H $168.20
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- H 46.18
- NBIX 67.38
- Support Level
- H $151.06
- NBIX $133.26
- Resistance Level
- H $163.55
- NBIX $140.00
- Average True Range (ATR)
- H 4.23
- NBIX 3.08
- MACD
- H -0.93
- NBIX 0.68
- Stochastic Oscillator
- H 20.89
- NBIX 69.03
About H Hyatt Hotels Corporation
Hyatt is an operator of owned (4% of total rooms) and managed and franchised (96%) properties across around 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 54% Americas, 22% rest of world, and 23% Asia-Pacific.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.